Fecal Microbiota Transplantation (FMT) in Ulcerative Colitis
To know if stool transplant from a healthy person into an ulcerative colitis patient can help treat the disease.
To know if stool transplant from a healthy person into an ulcerative colitis patient can help treat the disease.
To better understand the genetic changes that make children susceptible to the development of autism spectrum disorder, and to study how these changes influence clinical outcomes.
To investigate the connection between diet, genetics, and diseases in Hispanic / Latino youth.
To improve patient care and achieve the best health outcomes possible for children with IBD.
The purpose of the study is to collect information from children 0-18 years of age with all types of pancreatitis to determine the number of children diagnosed with this condition, understand the causes and progression of the disease, and review laboratory and imaging findings as well as responses to any treatments given.
To advance research on Minimal Change Disease (MCD), Focal and Segmental Glomerulosclerosis (FSGS), and Membranous Nephropathy (MN) that define nephrotic syndrome.
This research is being done to test the safety and effectiveness of intranasal carbetocin to treat Prader Willi Syndrome.
There is currently a lack of information on critical questions surrounding laterality of ureteropelvic junction obstruction (UPJO), the difference between extrinsic and intrinsic obstruction, the utility of retrograde pyelogram, and the appropriate management for patients with concurrent UPJO and ureterovesical junction obstruction (UVJO). Therefore, we propose first a retrospective study of all pyeloplasty’s completed at CHLA for UPJO to answer some of these critical questions. The results of this study may inform future studies in this realm. We will retrospectively review all cases of pyeloplasty completed at CHLA (from 2000 through present) to identify differences in outcomes.
To find out the effects of a chemical in Stevia on the symptoms of NAFLD.
To evaluate the efficacy of tofacitinib based on remission in pediatric participants with moderately to severely active Ulcerative Colitis (UC).